366 related articles for article (PubMed ID: 11888589)
21. [Diagnostic value of somatostatin receptor scintigraphy with indium-111 pentetreotide in small-cell bronchial carcinoma].
Hoefer M; Schmidt S; Welter J; Kirsch CM; Ukena D; Sybrecht GW
Pneumologie; 1998 Feb; 52(2):106-12. PubMed ID: 9557059
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
23. Tumour-induced osteomalacia: An emergent paraneoplastic syndrome.
Alonso G; Varsavsky M
Endocrinol Nutr; 2016 Apr; 63(4):181-6. PubMed ID: 26718193
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
25. [Somatostatin receptor scintigraphy in a patient with metastatic hemangiopericytoma].
Müller V; Klutmann S; Clausen M
Nuklearmedizin; 2003 Jun; 42(3):N13-4. PubMed ID: 12848152
[No Abstract] [Full Text] [Related]
26. Somatostatin receptor imaging in patients with sarcoidosis.
Kwekkeboom DJ; Krenning EP; Kho GS; Breeman WA; Van Hagen PM
Eur J Nucl Med; 1998 Sep; 25(9):1284-92. PubMed ID: 9724378
[TBL] [Abstract][Full Text] [Related]
27. [Detection of somatostatin receptors in tumors in the area of the head and neck and their clinical importance].
Kau RJ; Wagner-Manslau C; Saumweber DM; Arnold W
Laryngorhinootologie; 1994 Jan; 73(1):21-6. PubMed ID: 7908199
[TBL] [Abstract][Full Text] [Related]
28. Coexisting hyperparathyroidism and oncogenic osteomalacia: Sestamibi and somatostatin receptor scintigraphy.
Nguyen BD
Clin Nucl Med; 2006 Oct; 31(10):648-51. PubMed ID: 16985379
[No Abstract] [Full Text] [Related]
29. Oncogenic osteomalacia.
Sundaram M; McCarthy EF
Skeletal Radiol; 2000 Mar; 29(3):117-24. PubMed ID: 10794548
[No Abstract] [Full Text] [Related]
30. In vivo inaccessibility of somatostatin receptors to 111In-pentreotide in primary renal cell carcinoma.
Montravers F; Rousseau C; Doublet JD; Gattengo B; Allard S; Fouret P; Bernaudin JF; Thibault P; Talbot JN
Nucl Med Commun; 1998 Oct; 19(10):953-61. PubMed ID: 10234675
[TBL] [Abstract][Full Text] [Related]
31. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous cavernous hemangioma visualized on an indium-111-octreotide scan.
Winter PF; Lapke J; Winek R
J Nucl Med; 1996 Sep; 37(9):1516-7. PubMed ID: 8790204
[TBL] [Abstract][Full Text] [Related]
33. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours.
Chiti A; Briganti V; Fanti S; Monetti N; Masi R; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):42-9. PubMed ID: 10932600
[TBL] [Abstract][Full Text] [Related]
34. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
35. Osteomalacia by a mesenchymal-FGF23-producing tumour: Successful treatment with radiofrequency ablation. A case report.
Igney-Oertel A; Artunc F; Henes J; Hoffmann R; Clasen S
Joint Bone Spine; 2016 Oct; 83(5):603-4. PubMed ID: 27006265
[No Abstract] [Full Text] [Related]
36. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
[TBL] [Abstract][Full Text] [Related]
37. Perioperative management of patients with severe hypophosphataemia secondary to oncogenic osteomalacia: Our experience and review of literature.
Verma A; Tewari S; Kannaujia A
Indian J Anaesth; 2017 Jul; 61(7):590-593. PubMed ID: 28794533
[TBL] [Abstract][Full Text] [Related]
38. [Somatostatin receptor scintigraphy].
Rasmussen K; Nielsen JT; Rehling M
Ugeskr Laeger; 2005 Dec; 167(49):4647-50. PubMed ID: 16336855
[TBL] [Abstract][Full Text] [Related]
39. Phosphaturic mesenchymal tumors: radiological aspects and suggested imaging pathway.
Hussein MAM; Cafarelli FP; Paparella MT; Rennie WJ; Guglielmi G
Radiol Med; 2021 Dec; 126(12):1609-1618. PubMed ID: 34453276
[TBL] [Abstract][Full Text] [Related]
40. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
Balon HR; Goldsmith SJ; Siegel BA; Silberstein EB; Krenning EP; Lang O; Donohoe KJ;
J Nucl Med; 2001 Jul; 42(7):1134-8. PubMed ID: 11438641
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
